| Ytd | 29.92% | |
| 1y | 116.20% |
| Open | 20.59 | Prev Close | 20.45 | Low | 19.71 | High | 20.64 | Mkt Cap | 1.52B |
| Vol | 63.75K | Avg Vol | 889.24K | EPS | -2.29 | P/E | -8.93 | Forward P/E | 68.03 |
| Beta | 0.86 | Short Ratio | 12.14 | Inst. Own | 115.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 13.47 | 200-d Avg | 13.51 | 1yr Est | 28.33 |
XNCR News
U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings exp
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co
Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets ac
Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and lowers the
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discov
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcrip
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its 200-day moving average during trading
Pre-Market Stock Futures: After a volatile start to the week, futures are trading lower on Tuesday.
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has been given a consensus recommendation of "Moderate
Xencor, Inc. (NASDAQ: XNCR - Get Free Report)'s stock price gapped down before the market opened on
On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical co
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from t
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
During Monday's trading, 1214 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday